The Lancet HIV
Издатель: Elsevier · ISSN 2352-3018 · 40 статей
- Harm reduction makes uneven progress in Tanzania
- Global, regional, and national burden of HIV/AIDS, 1990–2023, with the estimated burden attributable to intimate partner violence and forecasted impacts of funding cuts through 2030: results from the Global Burden of Disease Study 2023
- Taking HIV outreach from the streets to the apps in Morocco
- Social sciences at the centre of HIV stigma reduction
- Trends in HIV-1 transmission in Switzerland: a retrospective molecular epidemiology study
- Psychedelic-assisted therapy research for people with HIV
- Early lessons from lenacapavir PrEP roll-out in Zimbabwe
- Turkish Government crackdown on HIV and LGBTQ+ groups
- Ebola virus disease outbreaks and HIV control
- Advancing a fixed-dose combination for children with HIV
- Differentiated service delivery and self-care in HIV
- Correction to Lancet HIV 2026; 13: e478–89
- Correction to Lancet HIV 2026; 13: e440–51
- Correction to Lancet HIV 2026; 13: e557–68
- Safety and immunogenicity of one or two doses of the rVSVΔG-ZEBOV-GP Ebola virus vaccine in adults and adolescents living with HIV: a phase 2, multicentre, double-blind, randomised, placebo-controlled trial
- Expediting a UNIVERSAL first-line regimen of a dolutegravir–emtricitabine–tenofovir alafenamide fixed-dose ratio for children living with HIV older than 4 weeks: a 24-week, open-label, single-arm, phase 1–2, pharmacokinetic, safety, and antiviral activity trial
- Plasma dolutegravir exposure testing to identify people with HIV at highest risk for dolutegravir resistance (ITREMA-2): a two-centre, prospective implementation study in South Africa
- Programmatic effectiveness of tuberculosis preventive treatment for people with HIV in six high-tuberculosis-burden countries (PROTECT): a prospective cohort study and meta-analysis
- Epidemiology and management of HIV-2
- Metabolic dysfunction-associated steatotic liver disease in people living with HIV: a framework for integrated screening and care
- Reimagining HIV service integration
- Aftershocks: Trump 2.0, Public Health, and Our Better Angels, José M Zuniga. Gatekeeper Press (2026), 534, ISBN: 9781662976346
- Pharmacokinetics and safety of dolutegravir in term neonates exposed to HIV-1 (IMPAACT 2023): a phase 1, open-label, multicentre study
- South Africa's paediatric HIV tracking gap
- Fiji's national HIV emergency
- Expanding access to lenacapavir in low-income and middle-income countries
- Low-level viraemia in children living with HIV
- Correction to Lancet HIV 2026; 13: e30–39
- Correction to Lancet HIV 2026; 13: e569–610
- Integrating long-acting injectable cabotegravir for HIV prevention into the Brazilian public health system (ImPrEP CAB Brasil): a hybrid type-2 implementation-effectiveness cohort study